Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Share-based Compensation (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Share-based Compensation over the past 3 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $1.8 million for Q4 2025, up 100.11% from a year ago — trailing twelve months through Dec 2025 was $4.9 million (up 19.21% YoY), and the annual figure for FY2025 was $6.0 million, up 25.93%.
  • Share-based Compensation for Q4 2025 was $1.8 million at Tonix Pharmaceuticals Holding, up from $1.2 million in the prior quarter.
  • Over the last five years, Share-based Compensation for TNXP hit a ceiling of $2.8 million in Q1 2023 and a floor of $700000.0 in Q3 2024.
  • Median Share-based Compensation over the past 3 years was $1.4 million (2024), compared with a mean of $1.5 million.
  • Biggest five-year swings in Share-based Compensation: crashed 66.67% in 2024 and later surged 100.11% in 2025.
  • Tonix Pharmaceuticals Holding's Share-based Compensation stood at $2.0 million in 2023, then plummeted by 56.13% to $894000.0 in 2024, then surged by 100.11% to $1.8 million in 2025.
  • The last three reported values for Share-based Compensation were $1.8 million (Q4 2025), $1.2 million (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.